Vistagen Therapeutics Inc VTGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen to Present at Psych Congress 2026
Trading Information
- Previous Close Price
- $0.19
- Day Range
- $0.18–0.20
- 52-Week Range
- $0.16–5.14
- Bid/Ask
- $0.21 / $0.21
- Shares Outstanding
- 46.19M
- Market Cap
- $9.21M
- Volume/Avg
- 2M / 10M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
- Website
- https://www.vistagen.com
Valuation
Metric | VTGN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | 3.39 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VTGN |
|---|---|
Quick Ratio | 2.38 |
Current Ratio | 2.64 |
Interest Coverage | — |
Quick Ratio
VTGN
Profitability
Metric | VTGN |
|---|---|
Return on Assets (Normalized) | −110.47% |
Return on Equity (Normalized) | −145.78% |
Return on Invested Capital (Normalized) | −144.60% |
Return on Assets
VTGN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|?XQbT! | LOCK|bC$sd | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|V^c!dv | LOCK|<<>t | $99B | |||
| Moderna Inc MRNA | LOCK|^?<?PjJ | LOCK|xhr | $84B | |||
| argenx SE ADR ARGX | LOCK|%X$y#?V | LOCK|SNk | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|w&x?!$ | LOCK|^l | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|T@tG%># | LOCK|Z?!Fj | $31B | |||
| Incyte Corp INCY | LOCK|<X$P@% | LOCK|mHQ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|SqKfWH! | LOCK|$PX | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>jh<$^g | LOCK|?dRm | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^j<xJ@ | LOCK|$$ | $15B |